Advertisement

Advertisement

Most Read Stories
FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-Positive Breast Cancer
FDA Approves Pembrolizumab for the First-Line Treatment of MSI-H/dMMR Colorectal Cancer
Study Finds Significant Variation in Hispanic Patients’ Trust of Cancer Information Sources
Real-World Data Show Survival Benefit for Adjuvant Immunotherapy in Stage III Melanoma
FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma
Addition of First-Line Atezolizumab to Vemurafenib and Cobimetinib in Patients With Unresectable Advanced BRAF V600–Mutant Melanoma
Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma
Addition of an ATR Inhibitor to Gemcitabine in Platinum-Resistant High-Grade Serous Ovarian Cancer
Novel Antibody-Drug Conjugate Shows Efficacy in Women With Pretreated, Metastatic HER2-Positive Breast Cancer
Risk of Breast Cancer Recurrence: Serum Detection of Nonadherence to Adjuvant Tamoxifen
Management of HER2-Positive Breast Cancer: Business as Usual?
Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Pancreatic Cancer Across Age Groups: Additional Analysis of the POLO Trial
When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance?
Novel Radiopharmaceutical May Aid in Imaging for Patients With Neuroendocrine Tumors and Liver Metastases
A Visiting Resident Oncologist’s Training During the COVID-19 Pandemic
Adjuvant Osimertinib in Early-Stage EGFR-Positive NSCLC
Pembrolizumab Doubles Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer
Biomarker Combination May Help Predict Response to Immunotherapy in Patients With Metastatic Urothelial Carcinoma
Fallopian Tube Removal May Protect Premenopausal Women at High Risk for Ovarian Cancer From Some Surgical Side Effects

Advertisement

Advertisement



Advertisement